AstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in patients who have just been treated with chemo, in trial re
Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.
China has carved itself a place as a major player in the pharma industry due to the number of clinical trials it is running, thanks to the reforms it has put in place.
Johnson & Johnson lawyers are gearing up to appeal a court ruling, which rewarded billions to 22 women in a case linking ovarian cancer and use of J&J's signature Baby Powder.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.